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Drug-resistant tuberculosis is caused by transmission 
of resistant strains of Mycobacterium tuberculosis and by 
acquisition of resistance through inadequate treatment. 
We investigated the clinical and molecular features of 
the disease in 2 families after drug-resistant tuberculosis 
was identifi ed in 2 children. The fi ndings demonstrate the 
potential for resistance to be transmitted and amplifi ed 
within families. 
The devastating effects of extensively drug-resistant tuberculosis (XDR TB) gained international attention 
after the 2006 outbreak in Tugela Ferry, South Africa. The 
evolution of the epidemic is the result of transmission of 
resistant strains and strain acquisition of resistance through 
inadequate treatment (1). Multidrug-resistant (MDR) TB 
is disease caused by Mycobacterium tuberculosis that is 
resistant to isoniazid and rifampin, and XDR TB is disease 
caused by M. tuberculosis that is additionally resistant to a 
fl uoroquinolone and an injectable second-line anti-TB drug. 
Because children usually have transmitted resistance (2), 
they can be seen as the end of a sequence of transmission 
events. We describe investigations of 2 families after the 
identifi cation of children with drug-resistant TB in terms 
of clinical features and molecular characteristics of the 
isolates.
The Study
This investigation was conducted in a suburban 
community of Cape Town, South Africa, where TB 
incidence was 978/100,000 population in 2009 (Health 
Systems Trust). Since 1994, microbiological samples from 
all patients treated for TB in this area have been sent to 
the research laboratory at Tygerberg Hospital, Stellenbosch 
University. From 2008 through 2010, two children from 
this community received a diagnosis of MDR TB.
Information was obtained from several sources to 
document the sequence of events that culminated in the 
development of MDR TB in each child. A home visit was 
made, and the family was interviewed after written informed 
consent was obtained. Family members were included if 
they either lived with or spent substantial amount of time 
with the child (3). Information on TB diagnosis, treatment, 
and outcome was obtained at interview. If a family member 
was identifi ed as having had TB, family contacts of that 
person were included. Searches for case notes for those 
included were made at the local clinic, the academic 
hospitals, and the regional TB hospital responsible for 
drug-resistant TB management. Also, the local clinic TB 
register was consulted. The investigation was approved by 
the Stellenbosch University Ethics Committee.
Sputum samples from the 2 families were identifi ed, and 
isolates were genotyped by spoligotyping (4) and IS6110 
DNA fi ngerprinting (5). Strains were identifi ed according 
to distinct IS6110 banding patterns by using Gelcompar 
II (Applied Maths, Sint-Martens-Latem, Belgium) or 
characteristic spoligotype pattern (6). Mutations conferring 
resistance to isoniazid, rifampin, ethambutol, pyrazinamide, 
ofl oxacin, and amikacin were determined by DNA 
sequencing of the inhA promoter, katG, rpoB, embB, pncA, 
gyrA, and rrs genes, respectively (7).
A 19-month-old girl (A3) received a diagnosis of TB 
in March 2008 after a 6-month course of preventive therapy 
with isoniazid. She was brought for assessment with a 
2-weeek history of cough, respiratory distress, and fever. 
She had contact with a patient with pre–XDR TB (MDR 
TB resistant to either a fl uoroquinolone or a second-line 
injectable drug), and therefore the following antimicrobial 
drugs were administered: capreomycin, ethionamide, 
ethambutol, para-aminosalicylic acid, terizidone, 
clarithromycin, and high-dose isoniazid. Gastric aspirate 
samples were sent to the National Health Laboratory 
Service; M. tuberculosis grew in culture and was resistant 
to rifampin, isoniazid, and ofl oxacin and susceptible to 
amikacin and ethionamide. She received treatment for 18 
months from the time of her fi rst negative culture (the fi rst 6 
months included the injectable medication) and recovered.
Patient 1’s family consisted of 18 persons (Figure 1). 
The husband of her aunt (A2) had drug-resistant TB. He 
cared for the girl on a daily basis. He had received treatment 
initially for drug-susceptible TB; this was changed to MDR 
TB therapy when resistance to rifampin and isoniazid was 
determined and then to XDR TB treatment when resistance 
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to second-line drugs was discovered. He subsequently 
died. His mother (A1) had repeatedly dropped out of 
treatment, and drug-resistant TB was fi nally diagnosed in 
1998. She refused further treatment and died in 2003. The 
clinical chronology is shown in Figure 2; molecular details 
regarding the samples analyzed are shown in the Table.
A 13-year-old girl (B5) was identifi ed in April 2009 
as a contact of multiple family members with XDR TB. 
She was asymptomatic, but a chest radiograph showed 
abnormalities. A regimen was begun of capreomycin, 
ethionamide, pyrazinamide, terizidone, para-aminosalicylic 
acid, co-amoxicillin/clavulanic acid, clarithromycin, 
linezolid, and high-dose isoniazid. M. tuberculosis, cultured 
from a sputum sample, was resistant to isoniazid, rifampin, 
ethambutol, ofl oxacin, and amikacin. Capreomycin was 
given for 6 months, and she received treatment for 18 
months in total. The condition was cured.
Patient 2’s family is depicted in Figure 1. The eldest 
brother (B1) had been in prison, and TB developed soon 
after his release in 1998. First-line treatment was begun, 
but he died soon afterward. TB then developed in his sister 
(B2), mother (B3), and brother (B4). All were given fi rst-
line therapy, which was changed, when resistance profi les 
became available, to the regimen for MDR TB and, for the 
brother, to the regimen for XDR TB. All 3 patients died. 
A chronology is shown in Figure 2; molecular details 
regarding the samples are provided in the Table.
Conclusions
In family 1, the uncle’s mother (A1) had pre–XDR 
TB and probably transmitted it to her son (A2). He likely 
transmitted it to his niece (A3). Strains for all 3 were 
identical. In family 2, whether the oldest brother (B1) 
had drug-resistant TB is unknown. His sister (B2) had 
pre–XDR TB; then, in sequence, XDR TB developed in 
her mother (B3), brother (B4), and sister (B5), caused by 
a strain identical to hers. This investigation, therefore, 
demonstrates the potential for resistance to be transmitted 
and amplifi ed within families.
Other than the 2 index case-patients (A3 and B5), 
all were initially given fi rst-line therapy and received 
treatment until drug susceptibility test (DST) results 
became available, often despite a drug-resistant contact 
being known. Local policy is to diagnose TB solely from 
sputum smear in new patients who have no risk factors 
for drug resistance. Retreatment patients and those at risk 
for resistance have strains tested for drug susceptibility to 
rifampin and isoniazid. If MDR TB is diagnosed, DST to 
second-line drugs is then performed. Giving inadequate 
regimens not only leads to more advanced disease until 
effective treatment is initiated but also risks amplifying 
resistance (8,9). For a patient with TB symptoms who is 
in contact with a drug-resistant TB patient, it is essential to 
obtain microbiological samples and then start treating the 
disease according to the DST results for the source case. If a 
less-resistant organism is grown, treatment can be changed. 
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Figure 1. Patients with drug-resistant tuberculosis in families 1 
(A) and 2 (B), South  Africa, 2008–2010. Gray shading indicates 
person identifi ed with tuberculosis; arrows indicate child index 
case-patients; circles indicate female family members; squares 
indicate male family members. 
Figure 2. Chronology of tuberculosis 
treatment and outcomes for 2 families 
with drug-resistant tuberculosis 
(TB), South Africa, 2008–2010. 
MDR TB, multidrug-resistant TB; 
XDR TB, extensively drug-resistant 
TB. A color version of this fi gure is 
available online (wwwnc.cdc.gov/
EID/article/18/8/11-1650-F2.htm).
In the context of multiple possible TB sources, deciding on 
treatment is challenging. Consideration must be given to the 
infectiousness of potential sources as well as the intensity, 
frequency, and duration of exposures. Local policy is to 
carry out household contact tracing for drug-resistant TB 
patients. Although this tracing occurs infrequently, we 
demonstrate the value of careful investigation of contacts to 
identify those who may have subclinical disease that could 
be treated at an early stage. Given the social interactions, 
chronology of illness, and the results of mycobacterial 
cultures, the transmission sequence in these cases likely 
occurred as described. However, in both clusters, the strain 
identifi ed was the predominant local strain and is a potential 
confounder to the transmission lines suggested.
With the rollout of rapid, genotypic diagnostic 
tests (10), which ultimately should be extended to all 
persons suspected of having TB, more drug-resistant TB 
may be diagnosed correctly and earlier. If this leads to 
prompt, appropriate treatment, further transmission and 
amplifi cation of resistance could be reduced. For XDR TB 
treatment, drug options that are not only new to the patient 
but also new to the community must be available. The use 
of linezolid and other novel drugs will become crucial in the 
management of an evolving drug-resistant TB epidemic.
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Table. Gene sequencing, IS6110 DNA fingerprinting, and genotype results for isolates from members of 2 families with drug-resistant 
tuberculosis, South Africa, 2008–2010* 
Family and family 
member ID no. 
Gene† IS6110
cluster 
no.
rpoB inhA katG embB gyrA pncA rrs 1401 
R H H E F Z A 
Family 1          
 Uncle’s mother A1 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
WT 213 
 Uncle A2 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
WT 213 
 Index child A3 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
WT § 
Family 2          
 Oldest brother‡ B1         
 Sister B2 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
WT 213 
 Mother B3 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
1401,
ACG?GCG
213
 Other brother B4 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90,
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
1401,
ACG?GCG
213
 Index child B5 531, 
TCG?TTG
WT 315, 
AGC?ACC 
306,
ATG?ATA 
90
GCG?GTG
160,
ACA?GCA;
100,
ACC?ATC
1401,
ACG?GCG
§
*All isolates were Mycobacteria tuberculosis Beijing genotype. The earliest sample available for each patient is shown; in all instances in which >1 sample 
was available for a patient, all samples demonstrated identical gene sequence and strain type results. ID, identification; R, rifampin; H, isoniazid; E, 
ethambutol; F, fluoroquinolones; Z, pyrazinamide; A, aminoglycosides, WT, wild type. 
†Numbers indicate specific mutations, which are shown. 
‡Tuberculosis developed and patient died before systematic sample collection and storage. No culture or drug susceptibility testing was requested for 
sample. 
§Only spoligotyping performed because isolates repeatedly lost viability on culture. 
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